Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704587 | 0.88 | TRPM8 (0.57) | CTSBCTSSCTSLCTSKTRPM8 | |
| SCHEMBL5704586 | 0.85 | LTA4H (0.53) | TRPM8CTRB1ITGB3ITGA2B | |
| SCHEMBL7435196 | 0.85 | CTSB (0.59) | CTSBCTSSCTSLCASP1F2 | |
| SCHEMBL5704657 | 0.84 | TRPM8 (0.51) | CTSBCTSSCTSLCTSKTRPM8 | |
| SCHEMBL6282238 | 0.80 | CMA1 (0.54) | — | |
| Acetone SCHEMBL7365925 | 0.79 | CTSB (0.53) | CTSBCTSSCTSLCASP1F2 | |
| SCHEMBL4634963 | 0.79 | CTSB (0.72) | CTSBCTSSCTSLCASP1F2 | |
| SCHEMBL18623602 | 0.79 | CTSB (0.72) | CTSBCTSSCTSLCASP1F2 | |
| SCHEMBL22764775 | 0.79 | CTSB (0.72) | CTSBCTSSCTSLCASP1F2 | |
| SCHEMBL7428630 | 0.79 | TRPM8 (0.55) | CTSBCTSSCTSLCTSKTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | CTSB 26/4885CTSS 10/4885CTSL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.